This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of 18.37% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
by Zacks Equity Research
Vertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of Trikafta/Kaftrio in U.S. and ex-U.S. markets drive the top line.
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
by Zacks Equity Research
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
by Zacks Equity Research
Alpine Immune Sciences (ALPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 146.88% and 346.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
StoneCo (STNE) to Post Q4 Earnings: What's in the Offing?
by Zacks Equity Research
StoneCo's (STNE) fourth-quarter 2023 performance will likely reflect strength in its financial services and software business.
Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season?
by Zacks Equity Research
Alpine Immune Sciences (ALPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Revenue Decline Impact Jabil's (JBL) Q2 Earnings?
by Zacks Equity Research
Jabil (JBL) is expected to report a top-line contraction year over year in the second quarter of fiscal 2024, owing to soft demand trends in several business segments.
Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Adobe's (ADBE) first-quarter fiscal 2024 results are expected to reflect gains from the solid momentum across the Digital Media and Digital Experience segments.
Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SentinelOne (S) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
SentinelOne's (S) fourth-quarter fiscal 2024 performance is expected to have benefited from its robust growth in the Singularity platform.
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 13.04% and 11.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cybin Inc. (CYBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alpine Immune Sciences, Inc. (ALPN) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.
Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical
by Zacks Equity Research
Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
Wall Street Analysts See a 56.25% Upside in Alpine Immune Sciences, Inc. (ALPN): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Alpine Immune Sciences, Inc. (ALPN) points to a 56.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Wall Street Analysts Think Alpine Immune Sciences, Inc. (ALPN) Could Surge 79.37%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 79.4% in Alpine Immune Sciences, Inc. (ALPN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.